| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Niraj Narendra Ravani, Pramod H Katk. Iloperidone-induced ejaculatory dysfunction: A case series. Indian journal of psychiatry. vol 58. issue 1. 2016-03-17. PMID:26985111. |
iloperidone, a new dopamine type 2 and serotonin type 2a antagonist similar to risperidone, provides better efficacy with lesser extra-pyramidal side effects. |
2016-03-17 |
2023-08-13 |
Not clear |
| T F Meert, F Awouter. Central 5-HT2 antagonists: A preclinical evaluation of a therapeutic potential. Acta neuropsychiatrica. vol 2. issue 4. 2016-03-09. PMID:26952556. |
a preclinical evaluation is presented of the serotonin 5-ht2 antagonists ritanserin and risperidone. |
2016-03-09 |
2023-08-13 |
Not clear |
| G Ammar, W J Naja, A Pelissol. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies]. L'Encephale. vol 41. issue 3. 2016-03-02. PMID:25439852. |
few trials have investigated selective serotonin reuptake inhibitors (ssri) or snri resistant generalized anxiety disorder showing a failure of adjunctive therapy with olanzapine, quetiapine, ziprasidone and risperidone. |
2016-03-02 |
2023-08-13 |
Not clear |
| Kalliopi N Nikolaou, Rossetos Gournellis, Ioannis Michopoulos, Georgios Dervenoulas, Christos Christodoulou, Athanasios Douzeni. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome? Annals of general psychiatry. vol 14. 2015-11-20. PMID:26583039. |
neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome? |
2015-11-20 |
2023-08-13 |
Not clear |
| Kalliopi N Nikolaou, Rossetos Gournellis, Ioannis Michopoulos, Georgios Dervenoulas, Christos Christodoulou, Athanasios Douzeni. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome? Annals of general psychiatry. vol 14. 2015-11-20. PMID:26583039. |
the diagnosis of serotonin syndrome was challenging due to the relatively low dose of clomipramine, an increase of risperidone which had taken place before clomipramine administration and clinical symptoms which could be attributed to both serotonin and neuroleptic malignant syndrome. |
2015-11-20 |
2023-08-13 |
Not clear |
| Luciana Romina Frick, Micaela Bernardez-Vidal, Christian Hocht, Bonifacio Silvano Zanutto, Maximiliano Rapanell. Dual role of serotonin in the acquisition and extinction of reward-driven learning: involvement of 5-HT1A, 5-HT2A and 5-HT3 receptors. Behavioural brain research. vol 277. 2015-09-08. PMID:24949809. |
long evans rats were trained in an operant conditioning task while receiving fluoxetine (serotonin reuptake inhibitor, 10mg/kg), tianeptine (serotonin reuptake enhancer, 10mg/kg), buspirone (5-ht1a partial agonist, 10mg/kg), risperidone (5-ht2a antagonist, 1mg/kg), ondansetron (5-ht3 antagonist, 2mg/kg) or vehicle. |
2015-09-08 |
2023-08-13 |
rat |
| Canan Kursungoz, Mehmet Ak, Tulin Yani. Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats. Brain research. vol 1596. 2015-08-24. PMID:25449893. |
in this study, we investigated the circulating levels of hypothalamic neurohormones, which are related to appetite regulation; neuropeptide y (npy); alpha melanocyte stimulating hormone (α-msh); cocaine and amphetamine regulated transcript (cart); agouti-related peptide (agrp); and leptin in male wistar rats, which were treated with risperidone, a serotonin antagonist, for four weeks. |
2015-08-24 |
2023-08-13 |
rat |
| Chadi A Calarge, Trudy L Burns, Janet A Schlechte, Babette S Zeme. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. The Journal of clinical psychiatry. vol 76. issue 5. 2015-08-11. PMID:26035190. |
longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. |
2015-08-11 |
2023-08-13 |
Not clear |
| Chadi A Calarge, Trudy L Burns, Janet A Schlechte, Babette S Zeme. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. The Journal of clinical psychiatry. vol 76. issue 5. 2015-08-11. PMID:26035190. |
in a previous cross-sectional study, we found lower bone mass during treatment with selective serotonin reuptake inhibitors (ssris) and risperidone in youths. |
2015-08-11 |
2023-08-13 |
Not clear |
| Edna B Foa, Helen Blair Simpson, David Rosenfield, Michael R Liebowitz, Shawn P Cahill, Jonathan D Huppert, James Bender, Carmen P McLean, Michael J Maher, Raphael Campeas, Chang-Gyu Hahn, Patricia Imms, Anthony Pinto, Mark B Powers, Carolyn I Rodriguez, Page E Van Meter, Donna Vermes, Monnica T William. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-29. PMID:25375780. |
six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. |
2015-06-29 |
2023-08-13 |
Not clear |
| Edna B Foa, Helen Blair Simpson, David Rosenfield, Michael R Liebowitz, Shawn P Cahill, Jonathan D Huppert, James Bender, Carmen P McLean, Michael J Maher, Raphael Campeas, Chang-Gyu Hahn, Patricia Imms, Anthony Pinto, Mark B Powers, Carolyn I Rodriguez, Page E Van Meter, Donna Vermes, Monnica T William. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-29. PMID:25375780. |
to compare outcomes after 6-month maintenance treatment of adults diagnosed with obsessive-compulsive disorder (ocd) based on dsm-iv criteria who responded to acute treatment with serotonin reuptake inhibitors (sris) augmented by exposure and response prevention (ex/rp) or risperidone. |
2015-06-29 |
2023-08-13 |
Not clear |
| Keisuke Hazama, Atsuko Hayata-Takano, Kazuki Uetsuki, Atsushi Kasai, Naoki Encho, Norihito Shintani, Kazuki Nagayasu, Ryota Hashimoto, Dora Reglodi, Tsuyoshi Miyakawa, Takanobu Nakazawa, Akemichi Baba, Hitoshi Hashimot. Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice. PloS one. vol 9. issue 2. 2015-01-27. PMID:24586556. |
mice with homozygous disruption of the pacap gene display profound behavioral and neurological abnormalities that are ameliorated with the atypical antipsychotic and dopamine d2 and serotonin (5-ht)2 antagonist risperidone and the 5-ht2 receptor antagonist ritanserin; however, the underlying mechanisms remain unknown. |
2015-01-27 |
2023-08-12 |
mouse |
| b' Katarzyna Kami\\xc5\\x84ska, Krystyna Go\\xc5\\x82embiowska, Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacological reports : PR. vol 65. issue 5. 2014-08-25. PMID:24399710.' |
effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. |
2014-08-25 |
2023-08-12 |
rat |
| b' Katarzyna Kami\\xc5\\x84ska, Krystyna Go\\xc5\\x82embiowska, Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacological reports : PR. vol 65. issue 5. 2014-08-25. PMID:24399710.' |
several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors, in the treatment of drug resistant depression. |
2014-08-25 |
2023-08-12 |
rat |
| Judith Usall, Raquel López-Carrilero, Raquel Iniesta, Mercedes Roca, Montserrat Caballero, Roberto Rodriguez-Jimenez, Cristina Oliveira, Miguel Bernardo, Iluminada Corripio, Santiago Durán Sindreu, Jose Carlos González Piqueras, Ana Espliego Felipe, Blanca Fernandez de Corres, Angela Ibáñez, Raúl Huert. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. The Journal of clinical psychiatry. vol 75. issue 6. 2014-08-25. PMID:25004184. |
in this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia. |
2014-08-25 |
2023-08-13 |
Not clear |
| C Roger-Sánchez, M Rodríguez-Arias, J Miñarro, M A Aguila. Effects of risperidone on the acquisition and reinstatement of the conditioned place preference induced by MDMA. Brain research bulletin. vol 98. 2014-05-30. PMID:23892054. |
in the present study we have evaluated the capacity of the mixed serotonin (5-ht2a)/dopamine (da d2) antagonist risperidone to block acquisition and reinstatement of mdma induced-cpp. |
2014-05-30 |
2023-08-12 |
mouse |
| Katsutoshi Shioda, Koichi Nisijima, Makiko Kasai, Tatsuki Yoshino, Satoshi Kat. Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models. Neuroscience letters. vol 528. issue 1. 2014-05-02. PMID:22985508. |
risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models. |
2014-05-02 |
2023-08-12 |
Not clear |
| Katsutoshi Shioda, Koichi Nisijima, Makiko Kasai, Tatsuki Yoshino, Satoshi Kat. Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models. Neuroscience letters. vol 528. issue 1. 2014-05-02. PMID:22985508. |
in the present study, the involvement of no and glutamate, as well as the effect of risperidone, a potent 5-ht(2a) and d(2) (and a less potent d(1)) receptor antagonist, were investigated in animal models of 5-ht syndrome. |
2014-05-02 |
2023-08-12 |
Not clear |
| Katsutoshi Shioda, Koichi Nisijima, Makiko Kasai, Tatsuki Yoshino, Satoshi Kat. Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models. Neuroscience letters. vol 528. issue 1. 2014-05-02. PMID:22985508. |
these results indicate that no and glutamate may be involved in the development of 5-ht syndrome and that risperidone may be effective against neurotransmitter abnormalities in 5-ht syndrome. |
2014-05-02 |
2023-08-12 |
Not clear |
| Takeshi Tsujino, Hiroyuki Isayama, Yousuke Nakai, Yukiko Ito, Osamu Togawa, Nobuo Toda, Toshihiko Arizumi, Hirofumi Kogure, Keisuke Yamamoto, Suguru Mizuno, Yoko Yashima, Hiroshi Yagioka, Takashi Sasaki, Saburo Matsubara, Natsuyo Yamamoto, Kenji Hirano, Naoki Sasahira, Minoru Tada, Kazuhiko Koik. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. Journal of gastroenterology. vol 48. issue 8. 2014-03-19. PMID:23090004. |
in experimental models, risperidone, a selective serotonin 2a antagonist, ameliorated acute pancreatitis. |
2014-03-19 |
2023-08-12 |
Not clear |